30.07.2021 12:53:19
|
IDEXX Labs Raises FY21 View Above Market - Quick Facts
(RTTNews) - While announcing higher second-quarter results, IDEXX Laboratories, Inc. (IDXX), a veterinary diagnostics provider, raised its forecast for fiscal 2021 earnings and revenues above market.
The company now expects full-year earnings per share of $8.20 - $8.36, higher than previous estimate of $7.88 to $8.18. Earnings per share for the year is expected to grow 22 percent to 25 percent from last year.
The outlook revision reflects an increase of 1 percent - 1.5 percent in the organic revenue growth outlook and expectations for higher operating margins of 28.6 percent - 29.1 percent.
Further, the company now expects revenues of $3.170 billion to $3.205 billion, higher than earlier expected $3.105 billion to $3.160 billion.
On average, 10 analysts polled by Thomson Reuters expect earnings of $8.10 per share on revenues of $3.14 billion. Analysts' estimates typically exclude special items.
The revision reflects higher expectations for reported growth of 17 percent - 18.5 percent and organic growth of 14.5 percent - 16 percent, supported by projected CAG Diagnostics recurring revenue growth of 18 percent - 19.5 percent as reported and 16 percent - 17.5 percent organic.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu IDEXX Laboratoriesmehr Nachrichten
Analysen zu IDEXX Laboratoriesmehr Analysen
Aktien in diesem Artikel
IDEXX Laboratories | 398,50 | -1,26% |